C-myc oncogene gene dosage, serum CEA and CA-15.3 antigen levels, and cellular DNA values in relation to ex vivo chemosensitivity of primary human breast cancer

• Autorzy: Falkiewicz B. , Schlotter C.M. , Bosse U. , Bielawski K. , Vogt U.
• Języki publikacji: EN

Abstrakty

EN

A pilot study on relationships of selected molecular factors (c-myc oncogene average gene copy numbers (AGCN); serum CEA and CA 15.3 antigen levels; tumor cells' DNA values), to the ex vivo chemosensitivity of primary female human breast cancer in a modified adenosine triphosphate cell viability chemosensitivity assay (ATP-CVA), was performed. Four drug combinations were tested. A group of 75 cases of female primary breast cancer was assessed. Numerous correlations were found among molecular factors tested but none, with the exception of tumor grading, of these reflected ex vivo chemosensitivity of tumors tested. The results suggest that the parameters tested may not be important factors related to adjuvant chemoresponsiveness of primary human breast cancer to tested drug combinations

Słowa kluczowe

EN

antigen level; drug resistance; antineoplastic agent; chemosensitivity; tumour cell; antitumour drug; man; cellular DNA; oncogene; cancer; breast cancer

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2000
• Tom: 47
• Numer: 1
• Opis fizyczny: p.149-156

Twórcy

autor

Falkiewicz B.

• University of Gdansk, Gdansk, Poland

autor

Schlotter C.M.

autor

Bosse U.

autor

Bielawski K.

autor

Vogt U.

Bibliografia

• 1. Andreotti, P.E., Linder, D., Hartmann, D.M., Cree, I.A., Pazzagli, M. & Bruckner, H.W. (1994) TCA-100 tumour chemosensitivity assay: Differences in sensitivity between cultured tumour cell lines and clinical studies. J. Biolumin. Chemilumin. 9, 373-378.
• 2. Andreotti, P.E., Cree, I.A., Kurbacher, C.M., Hartmann, D.M., Linder, D., Harel, G., Gleiberman, I., Caruso, P.A., Ricks, S.H., Untch, M., Sartori, C. & Bruckner, H.W. (l995) Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: Clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res. 55, 5276-5282.
• 3. Beckmann, A., Vogt, U., Huda, N., Znker, K.S. & Brandt, B.H. (1999) Direct-double-differential PCR for gene dosage quantification of c-myc. Clin. Chem. 45, 141-143.
• 4. Berns, E.M.J.J., Foekens, J.A., Van Staveren, I.L., Van Putten, W.L.J., De Koning, H.Y.W.C.M., Portengen, H. & Klijn, J.G.M. (1995) Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment. Gene 159, 11-18.
• 5. Brandt, B., Vogt, U., Griwatz, C., Harms, F., Bosse, U. & Znker, K.S. (1994) Detection of amplified oncogenes by differential polymerase chain reaction; in Methods in DNA Amplification (Rolfs, A., Weber-Rolfs, I. & Finckh, U., eds.) pp. 55-64, Plenum Press, New York.
• 6. Brandt, B., Vogt, U., Harms, F., Bosse, U., Znker, K.S. & Assmann, G. (1995a) Double-differential PCR for gene dosage estimation of erbB oncogenes in benign and cancer tissues and comparison to cellular DNA content. Gene 159, 29-34.
• 7. Brandt, B., Vogt, U., Schlotter, C.M., Jackisch, C., Werkmeister, R., Thomas, M., Von Eiff, M., Bosse, U., Assmann, G. & Znker, K.S. (1995b) Prognostic relevance of aberrations in the erbB oncogenes from breast, ovarian, oral and lung cancers: Double-differential polymerase chain reaction (ddPCR) for clinical diagnosis. Gene 159, 35-42.
• 8. Clark, G.M. (1998) Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status? J. Natl. Cancer Inst. 90, 1320-1321.
• 9. Cortazar, P. & Johnson, B.E. (1999) Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J. Clin. Oncol. 17, 1625­1631.
• 10. Cree, I.A., Kurbacher, C.M., Untch, M., Sutherland, L.A., Hunter, E.M., Subedi, A.M.C., James, E.A., Dewar, J.A., Preece, P.E., Andreotti, P.E. & Bruckner, H.W. (1996) Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anti-Cancer Drugs 7, 630-635.
• 11. Cree, I.A. & Kurbacher, C.M. (1997) Individualizing chemotherapy for solid tumors is there any alternative? Anti-Cancer Drugs 8, 541-548.
• 12. De Vita, V.T., Jr. (1997) Principles of cancer management: Chemotherapy; in Cancer: Principles and Practice ofOncology (De Vita, V.T., Jr., Hellman, S. & Rosenberg, S.A., eds.) pp. 333- 347, Lippincott-Raven Publishers, Philadelphia.
• 13. Falkiewicz, B. & Vogt, U. (1999) In vitro prediction of cancer patients' response to chemotherapy, in Breast Cancer (Bonk, U. et al., ed.). Ullstein Medical Verlag Wiesbaden, Springer (in press).
• 14. Falkiewicz, B., Schlotter, C.M., Bosse, U., Bielawski, K., Podhajska, A.J. & Vogt, U. (1999) Chemosensitivity of primary human breast cancers in ATP-CVA assay in relationship to their oncogene status. 7th International Symposium on Molecular Aspects ofChemotherapy, 8-11 September 1999, Gdansk, Poland. Abstract Book, p. 94.
• 15. Hunter, E.M., Sutherland, L.A., Cree, I.A., Dewar, J.A., Preece, P.E., Wood, R.A.B., Linder, D. & Andreotti, P.E. (1993) Heterogeneity of chemosensitivity in human breast carcinoma: Use of an adenosine triphosphate (ATP) chemiluminescence assay. Eur. J. Surg. Oncol. 19, 242-249.
• 16. Koechli, O.R., Avner, B.P., Sevin, B.-U., Avner, B., Parras, J.P., Robinson, D.S. & Averette, H.E. (1993) Application of the adenosine triphosphate-cell viability assay in human breast cancer chemosensitivity testing: A report on the first results. J. Surg. Oncol. 54, 119-125.
• 17. Koechli, O.R., Sevin, B.-U., Schaer, G. & Haller, U. (1995) Application of the adenosine triphosphate-cell viability assay for pretherapeutic chemosensitivity testing in breast cancer. Geburtsh. Frauenheilk. 55, 7-16 (in German).
• 18. Kurbacher, C.M., Mallmann, P., Kurbacher, J.A., Hubner, H. & Krebs, D. (1996a) Chemosensitivity testing in gynaecological oncology: Experiences with an ATP-bioluminescence assay. Geburtsh. Frauenheilk. 56, 70-78 (in German).
• 19. Kurbacher, C.M., Cree, I.A., Brenne, U., Bruckner, H.W., Kurbacher, J.A., Mallmann, P., Andreotti, P.E. & Krebs, D. (1996b) Heterogeneity of in vitro chemosensitivity in perioperative breast cancer cells to mitoxantrone versus doxorubicin evaluated by a microplate ATP bioluminescence assay. Breast Cancer Res. Treat:. 41, 161-170.
• 20. Kurbacher, C.M., Bruckner, H.W., Cree, I.A., Andreotti, P.A. & Janat, M.M. (1999) A prospective clinical trial on individualized chemotherapy for recurrent ovarian cancer selected by the ex vivo ATP tumor chemosensitivity assay. Proc. Am. Soc. Clin. Oncol. 18, 1384 (abstract).
• 21. Molina, R. & Gion, M. (1998) Use of blood tumour markers in the detection of recurrent breast cancer. The Breast 7, 187-189.
• 22. Petty, R.D., Cree, I.A., Sutherland, L.A., Hunter, E.M., Lane, D.P., Preece, P.E. & Andreotti, P.E. (1994) Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity. Biochem. Biophys. Res. Commun. 199, 264-270.
• 23. Robertson, J.F.R., Jaeger, W., Szymendera, J.J., Selby, C., Coleman, R., Howell, A., Winstanley, J., Jonssen, P.E., Bombardieri, E., Sainsbury, J.R.C., Gronberg, H., Kumpulainen, E., Blamey, R.W. and Europen Group for Serum Tumour Markers in Breast Cancer (1999) The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. Eur. J. Cancer 35, 47-53.
• 24. Ryan, K.M. & Birnie, G.D. (1996) Myc oncogenes: the enigmatic family. Biochem. J. 314, 713-721.
• 25. Schlotter, C.M., Bosse, U., Falkiewicz, B., Bielawski, K. & Vogt, U. (1999) Correlation of erbB oncogene family gene dosages and erbB-2 expression to in vitro chemosensitivity of primary human breast cancers. Proc. Am. Soc. Clin. Oncol. 18, 409 (abstract).
• 26. Vogt, U., Bielawski, K., Schlotter, C.M., Bosse, U., Falkiewicz, B. & Podhajska, A.J. (1998a) Amplification of erbB-4 oncogene occurs less frequently than that of erbB-2 in primary human breast cancer. Gene 223, 375-380.
• 27. Vogt, U., Striehn, E., Bosse, U. & Klinke, F. (1998b) Is the combination of ATP cell viability chemosensitivity assay (ATP-CVA) and molecular prognostic factors able to detect NSCLC patients with good or poor response to chemotherapy? Thorac Cardiovasc. Surg. 46 (suppl. 1), 225 (abstract).
• 28. Vogt, U., Striehn, E., Bosse, U., Klinke, F. & Falkiewicz, B. (1999a) Lack of squamous cell lung carcinoma in vitro chemosensitivity to various drug regimens in the adenosine triphosphate cell viability chemosensitivity assay. Acta Biochim. Polon. 46, 299-302.
• 29. Vogt, U., Bielawski, K., Schlotter, C.M., Bosse, U., Podhajska, A.J. & Falkiewicz, B. (1999b). Relationship of c-myc and erbB oncogene family gene aberrations and other molecular factors to ex vivo chemosensitivity of ovarian cancer in the modified ATP-chemosensitivity assay. 7th International Symposium on Molecular Aspects ofChemotherapy, 8-11 September 1999, Gdansk, Poland. Abstract book, p. 95.
• 30. Zabel, M., Kaczmarek, A., Lukianow, R., Ramlau, R. & Gorny, A. (1992) Testowanie wrazliwosci komorek nowotworowych na cytostatyki w warunkach hodowli komorkowej. Nowotwory 42, 187-192 (in Polish).
• 31. Zabel, M., Kaczmarek, A., Rozmiarek, A. & Markowska, J. (1997) Test wrazliwosci komorek nowotworowych na cytostatyki in vitro, a efekt kliniczny. Wspolcz. Onkol. 2, 17-19 (in Polish).